Evidence map›Paper›PMID 42042786›Full record

ArticleVaccines2026

Neo-BCV: A Novel Bacterial Complex Vaccine Reshaping the Gut Microbiota to Enhance the Antitumor Immune Response.

Hairu Yang, Huiqin Zhu, Zilong Zhu, Lingyun Man, Qingfeng Pang, Tao Lu, Kecheng Xu, Zhenyi Wang, Peihua Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hairu YangDepartment of Oncology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi Medical Center, Nanjing Medical University, Wuxi 214023, China.
Huiqin ZhuDepartment of Oncology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi Medical Center, Nanjing Medical University, Wuxi 214023, China.
Zilong ZhuDepartment of Oncology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi Medical Center, Nanjing Medical University, Wuxi 214023, China.
Lingyun ManSchool of Medicine, Jiangnan University, Wuxi 214122, China.
Qingfeng PangSchool of Medicine, Jiangnan University, Wuxi 214122, China.ORCID 0000-0003-0679-4780
Tao LuSchool of Life Science, Beijing University of Chinese Medicine, Beijing 100029, China.
Kecheng XuOncology Department, National Key Clinical Specialty (Oncology), Biomedical Translational Research Institute, Fuda Cancer Hospital, Jinan University, Guangzhou 510632, China.
Zhenyi WangNational Research Centre for Translational Medicine at Shanghai, State Key Laboratory of Medical Genomics, Research Unit of Hematologic Malignancies Genomics and Translational Research of Chinese Academy of Medical Sciences, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Peihua LuDepartment of Oncology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi Medical Center, Nanjing Medical University, Wuxi 214023, China.ORCID 0009-0005-2855-8780

Funding

Basic Research Program of Jiangsu BK20241761Top Talent Support Program for young and middle-aged people of Wuxi Health Committee No. BJ2023023
6 · The paper itself

Abstract

backgroundLung cancer is the most common malignancy worldwide and has the highest mortality rate. Although therapeutic approaches have improved over recent years, the clinical efficacy of lung cancer treatment remains limited. Therefore, there is an urgent need to develop novel and effective immunotherapeutic strategies for lung cancer.

methodsIn this study, we constructed a novel bacterial complex vaccine (Neo-BCV, hereafter referred to as BCV) and investigated its anti-tumor effects and underlying mechanisms in a murine lung cancer model. We further explored the role of the gut microbiota, bile acid metabolism, and T-cell function in BCV-mediated anti-tumor immunity. In addition, we performed a preliminary evaluation of the clinical safety of BCV in human subjects.

resultsBCV treatment significantly enhanced the infiltration of CD4

conclusionsThis study demonstrates that BCV remodels the gut microbiota and enhances anti-tumor immunity by regulating the

Indexed as

Lactobacillus reuterinon-small cell lung cancertaurocholic acidtumor immunitytumor vaccines

Identifiers

PMID42042786
PMCPMC13120426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.